Known targets — ChEMBL curated mechanism
The experimentally established mechanism targets of Squalamine. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 18)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PTPN1 | P18031 | 2/20 | 0.89 |
| ▸ | SLC10A1 | Q14973 | 4/20 | 0.49 |
| ▸ | NR1H4 | Q96RI1 | 7/20 | 0.49 |
| ▸ | GPBAR1 | Q8TDU6 | 8/20 | 0.47 |
| ▸ | SLC10A2 | Q12908 | 4/20 | 0.46 |
| ▸ | ABCB11 | O95342 | 3/20 | 0.46 |
| ▸ | ENPP2 | Q13822 | 2/20 | 0.46 |
| ▸ | ABCC4 | O15439 | 1/20 | 0.46 |
| ▸ | PLA2G1B | P04054 | 1/20 | 0.46 |
| ▸ | MEN1 | O00255 | 2/20 | 0.45 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.45 |
| ▸ | LMNA | P02545 | 1/20 | 0.45 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.45 |
| ▸ | CHRM2 | P08172 | 1/20 | 0.45 |
| ▸ | ADRA2A | P08913 | 1/20 | 0.45 |
| ▸ | ADRA1A | P35348 | 1/20 | 0.45 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.45 |
| ▸ | CISD1 | Q9NZ45 | 1/20 | 0.45 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Squalamine SCHEMBL313361 | 0.99 | PTPN1 (0.90) | PTPN1SLC10A1NR1H4GPBAR1SLC10A2 | |
| Squalamine SCHEMBL29673379 | 0.99 | PTPN1 (0.90) | PTPN1SLC10A1NR1H4GPBAR1SLC10A2 | |
| Squalamine SCHEMBL22397773 | 0.97 | PTPN1 (0.86) | PTPN1SLC10A1NR1H4GPBAR1SLC10A2 | |
| Squalamine SCHEMBL23832402 | 0.96 | PTPN1 (0.96) | PTPN1SLC10A1NR1H4GPBAR1SLC10A2 | |
| Squalamine SCHEMBL23832395 | 0.96 | PTPN1 (0.96) | PTPN1SLC10A1NR1H4GPBAR1SLC10A2 | |
| Squalamine SCHEMBL23832393 | 0.96 | PTPN1 (0.96) | PTPN1SLC10A1NR1H4GPBAR1SLC10A2 | |
| Squalamine SCHEMBL20850040 | 0.96 | PTPN1 (0.97) | PTPN1SLC10A1NR1H4GPBAR1SLC10A2 | |
| Squalamine SCHEMBL21248627 | 0.96 | PTPN1 (0.97) | PTPN1SLC10A1NR1H4GPBAR1SLC10A2 | |
| Squalamine SCHEMBL22356672 | 0.96 | PTPN1 (0.97) | PTPN1SLC10A1NR1H4GPBAR1SLC10A2 | |
| Squalamine SCHEMBL12836 | 0.96 | PTPN1 (0.97) | PTPN1SLC10A1NR1H4GPBAR1SLC10A2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 17 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20260098052-A1 | HUMAN AMINOSTEROL ENT-03 COMPOUNDS, RELATED COMPOSITIONS COMPRISING THE SAME, AND METHODS OF USING THE SAME | ENTERIN, INC. (US) | 2026-04-09 | — | — | US | disclosed |
| US-12503485-B2 | Human aminosterol ENT-03 compounds, related compositions comprising the same, and methods of using the same | ENTERIN, INC. (US) | 2025-12-23 | — | — | US | disclosed |
| US-20250228873-A1 | C25 R AND S ISOMERS OF AMINOSTEROLS AND METHODS OF MAKING AND USING THE SAME | ENTERIN, INC. (US) | 2025-07-17 | — | — | US | disclosed |
| CN-114929724-B | Amino sterol ENT-03 compounds, related compositions comprising the same, and methods of use thereof | 因特尔公司 | 2024-12-10 | — | — | CN | disclosed |
| US-20240277732-A1 | COMPOSITIONS AND METHODS FOR TREATING BRAIN-GUT DISORDERS | ENTERIN, INC. (US) | 2024-08-22 | — | — | US | disclosed |
| US-20230321012-A1 | Methods To Treat Cancer With AMXT 1501 and DFMO | AMINEX THERAPEUTICS, INC. | 2023-10-12 | — | — | US | disclosed |
| WO-2023146842-A9 | C25 R AND S ISOMERS OF AMINOSTEROLS AND METHODS OF MAKING AND USING THE SAME | ENTERIN, INC. (US) | 2023-08-24 | — | — | WO | disclosed |
| WO-2023102402-A1 | METHODS TO TREAT CANCER WITH AMXT 1501 AND DFMO | AMINEX THERAPEUTICS, INC. (US) | 2023-06-08 | — | — | WO | disclosed |
| US-20230125585-A1 | DOSING PROTOCOLS AND REGIMENS FOR AMINOSTEROL TREATMENT | ENTERIN, INC. (US) | 2023-04-27 | — | — | US | disclosed |
| US-20230123701-A1 | HUMAN AMINOSTEROL ENT-03 COMPOUNDS, RELATED COMPOSITIONS COMPRISING THE SAME, AND METHODS OF USING THE SAME | ENTERIN, INC. (US) | 2023-04-20 | — | — | US | disclosed |
| EP-4142788-A2 | COMPOSITIONS COMPRISING ANTI-VEGF AND NANOPARTICLES AND METHODS OF USING THE SAME FOR THE TREATMENT OF ABNORMAL OR EXCESSIVE ANGIOGENESIS | Pham, Randal Tanh Hoang (US) | 2023-03-08 | — | — | EP | disclosed |
| US-20220372066-A1 | HUMAN SQUALAMINE DERIVATIVES (ENT-06), RELATED COMPOSITIONS COMPRISING THE SAME, AND METHOD OF USING THE SAME | ENTERIN, INC. (US) | 2022-11-24 | — | — | US | disclosed |
| US-11464789-B2 | Aminosterol compositions and methods of using the same for treating schizophrenia | ENTERIN, INC. (US) | 2022-10-11 | — | — | US | disclosed |
| US-11440936-B2 | Methods and compositions for stimulation of the intestinal enteroendocrine system for treating diseases or conditions related to the same | ENTERIN, INC. (US) | 2022-09-13 | — | — | US | disclosed |
| US-11419879-B2 | Methods for treating and preventing viral infections | ENTERIN, INC. (US) | 2022-08-23 | — | — | US | disclosed |
| CN-110087705-B | Multiphase gels | BVW控股公司 | 2022-08-05 | — | — | CN | disclosed |
| US-20220220148-A1 | METHODS AND COMPOSITIONS FOR STIMULATION OF THE INTESTINAL ENTEROENDOCRINE SYSTEM FOR TREATING DISEASES OR CONDITIONS RELATED TO THE SAME | ENTERIN INC. (US) | 2022-07-14 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (12 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230123701-A1 | HUMAN AMINOSTEROL ENT-03 COMPOUNDS, RELATED COMPOSITIONS COMPRISING THE SAME, AND METHODS OF USING THE SAME | CYP17A1, HSD17B13, HSD17B7 | PTPN1 4663/4885SLC10A1 254/4885NR1H4 69/4885 |
| US-20250228873-A1 | C25 R AND S ISOMERS OF AMINOSTEROLS AND METHODS OF MAKING AND USING THE SAME | DHCR7, HSD17B7, HSD3B1 | PTPN1 4819/4885SLC10A1 272/4885NR1H4 47/4885 |
| US-20220372066-A1 | HUMAN SQUALAMINE DERIVATIVES (ENT-06), RELATED COMPOSITIONS COMPRISING THE SAME, AND METHOD OF USING THE SAME | SQLE, ENTPD5, LSS | PTPN1 3977/4885SLC10A1 248/4885NR1H4 266/4885 |
| US-20230321012-A1 | Methods To Treat Cancer With AMXT 1501 and DFMO | SLC10A1, SLC7A11, NFXL1 | PTPN1 2887/4885SLC10A1 1/4885NR1H4 1112/4885 |
| US-20240277732-A1 | COMPOSITIONS AND METHODS FOR TREATING BRAIN-GUT DISORDERS | SLC10A2, FABP2, FABP7 | PTPN1 3943/4885SLC10A1 8/4885NR1H4 52/4885 |
| US-11464789-B2 | Aminosterol compositions and methods of using the same for treating schizophrenia | HSD17B7, HSD17B13, NR3C2 | PTPN1 3269/4885SLC10A1 369/4885NR1H4 389/4885 |
| US-20220220148-A1 | METHODS AND COMPOSITIONS FOR STIMULATION OF THE INTESTINAL ENTEROENDOCRINE SYSTEM FOR TREATING DISEASES OR CONDITIONS RELATED TO THE SAME | SI, VIP, ASNS | PTPN1 4093/4885SLC10A1 577/4885NR1H4 296/4885 |
| US-11440936-B2 | Methods and compositions for stimulation of the intestinal enteroendocrine system for treating diseases or conditions related to the same | SI, VIP, ASNS | PTPN1 4093/4885SLC10A1 577/4885NR1H4 296/4885 |
| US-11419879-B2 | Methods for treating and preventing viral infections | STING1, TSLP, MAVS | PTPN1 2620/4885SLC10A1 114/4885NR1H4 542/4885 |
| US-20230125585-A1 | DOSING PROTOCOLS AND REGIMENS FOR AMINOSTEROL TREATMENT | HSD3B1, HSD17B7, HSD11B1 | PTPN1 2492/4885SLC10A1 94/4885NR1H4 75/4885 |
| US-20260098052-A1 | HUMAN AMINOSTEROL ENT-03 COMPOUNDS, RELATED COMPOSITIONS COMPRISING THE SAME, AND METHODS OF USING THE SAME | HSD3B1, HSD3B2, HSD11B1 | PTPN1 3532/4885SLC10A1 53/4885NR1H4 40/4885 |
| US-12503485-B2 | Human aminosterol ENT-03 compounds, related compositions comprising the same, and methods of using the same | CYP17A1, HSD17B13, HSD17B7 | PTPN1 4663/4885SLC10A1 254/4885NR1H4 69/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.